



Article

Comparative Study of Hydroxytyrosol Acetate and Hydroxytyrosol in Activating Phase II Enzymes

Xuan Zou ^{1,2,†}, Mengqi Zeng ^{3,4,†}, Yuan Zheng ⁵, Adi Zheng ⁶, Li Cui ⁷, Wenli Cao ⁷, Xueqiang Wang ⁴, Jiansheng Liu ^{4,7}, Jie Xu ^{7,*} and Zhihui Feng ^{3,4,*}

- ¹ National & Local Joint Engineering Research Center of Biodiagnosis and Biotherapy, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China; zuseon@xjtu.edu.cn
 - ² Precision Medical Institute, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
 - ³ Frontier Institute of Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China
 - ⁴ School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao 266071, China; j.liu@xjtu.edu.cn (J.L.)
 - ⁵ Department of Pediatrics, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
 - ⁶ School of Medicine, Northwest University, Xi'an 710069, China
 - ⁷ Center for Mitochondrial Biology and Medicine, The Key Laboratory of Biomedical Information Engineering of Ministry of Education, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China
- * Correspondence: xj0322@xjtu.edu.cn (J.X.); zhifeng@mail.xjtu.edu.cn (Z.F.)
† These authors contributed equally to this work.

Abstract: Nuclear factor E2-related factor 2 (Nrf2) is fundamental to the maintenance of redox homeostasis within cells via the regulation of a series of phase II antioxidant enzymes. The unique olive-derived phenolic compound hydroxytyrosol (HT) is recognized as an Nrf2 activator, but knowledge of the HT derivative hydroxytyrosol acetate (HTac) on Nrf2 activation remains limited. In this study, we observed that an HT pretreatment could protect the cell viability, mitochondrial membrane potential, and redox homeostasis of ARPE-19 cells against a t-butyl hydroperoxide challenge at 50 μ M. HTac exhibited similar benefits at 10 μ M, indicating a more effective antioxidative capacity compared with HT. HTac consistently and more efficiently activated the expression of Nrf2-regulated phase II enzymes than HT. PI3K/Akt was the key pathway accounting for the beneficial effects of HTac in ARPE-19 cells. A further RNA-Seq analysis revealed that in addition to the consistent upregulation of phase II enzymes, the cells presented distinct expression profiles after HTac and HT treatments. This indicated that HTac could trigger a diverse cellular response despite its similar molecular structure to HT. The evidence in this study suggests that Nrf2 activation is the major cellular activity shared by HTac and HT, and HTac is more efficient at activating the Nrf2 system. This supports its potential future employment in various disease management strategies.

Keywords: hydroxytyrosol acetate; nuclear factor E2-related factor 2; phase II enzymes; oxidative stress



Citation: Zou, X.; Zeng, M.; Zheng, Y.; Zheng, A.; Cui, L.; Cao, W.; Wang, X.; Liu, J.; Xu, J.; Feng, Z. Comparative Study of Hydroxytyrosol Acetate and Hydroxytyrosol in Activating Phase II Enzymes. *Antioxidants* **2023**, *12*, 1834. <https://doi.org/10.3390/antiox12101834>

Academic Editors: Maria-Jose Alcaraz and Alessandra Napolitano

Received: 2 August 2023

Revised: 20 September 2023

Accepted: 30 September 2023

Published: 7 October 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

With human lifespan extensions and demographic shifts, the proportion of people over 60 years old has increased. This has led to an urgent need for an effective therapeutic strategy for age-related diseases such as age-related macular degeneration (AMD). In mammals, the macular region of the retina converges with the major photoreceptors; its degeneration causes central vision loss. AMD is a progressive degenerative disease of the macular region and is considered to be the leading cause of blindness in the elderly [1,2]. Retinal pigment epithelium (RPE) cells provide support for the survival and normal working of photoreceptors by performing several functions, including transporting nutrients and re-isomerizing visual pigment [3,4]. The RPE is susceptible to oxidative damage from intracellular free radicals or other external stimuli. It is generally believed

that accumulated oxidative damage caused by aging is the main factor for RPE dysfunction, which contributes to AMD [5]. Recent studies have demonstrated that GSH depletion and tert-butyl hydroperoxide (t-BHP) incubation induce RPE ferroptosis, identifying ferroptosis as a major contributor to oxidative-stress-mediated RPE cell death [6–8].

Nuclear factor E2-related factor 2 (Nrf2) is a key regulator of phase II detoxification in response to oxidative/xenobiotic stress. In normal conditions, Nrf2 binds to the Kelch-like ECH-associating protein 1 (Keap1) in a low-activity state. Under oxidative stress, Keap1 is modified to promote Nrf2 release and translocation into the nucleus [9]. Nrf2 translocation drives the expression of downstream antioxidative enzymes, known as phase II enzymes, including cytoprotective gene heme oxygenase 1 (HO-1) and H:quinone oxidoreductase (NQO1) [10–12]. Heme oxygenase catalyzes the degradation of ferrous iron, carbon monoxide, and bilirubin [13]. NQO1 participates in the regulation of superoxide reductase activity and NAD⁺ generation [14]. Nrf2 promotes glutathione levels by regulating genes for glutathione metabolism such as the glutamate-cysteine ligase catalytic subunit (GCLC) and modifier subunit (GCLM) [15]. In vitro studies have demonstrated that Nrf2 plays an important role in oxidative-stress-induced RPE cell death [16–18]. Accumulating evidence has revealed that HO-1 is involved in RPE ferroptosis [8,19]. Therefore, the activation of Nrf2/HO-1 signaling could be a potential target mechanism for the protection of the RPE from oxidative stress, which could be beneficial to AMD.

Olive oil has abundant phenolic compounds. Among them, hydroxytyrosol (HT) is the most effective antioxidant [20]. In recent decades, understanding the beneficial role of HT in the aging process has achieved significant progress. HT has demonstrated a potential protective effect in several age-related diseases, including neurodegenerative diseases and AMD [21]. Hydroxytyrosol acetate (HTac), a natural derivative of HT, is a major component in olive phenols, but has received limited attention. The concentration of both HT and HTac is affected by the cultivar and processing methods of olive oil. HT concentrations range from 18 to 177 μ M, whereas HTac concentrations are relative higher than HT and can range from 23 to 654 μ M in different types of olive oil [22]. HTac has been reported to possess antioxidant and anti-inflammatory activities [23], presenting a greater bioactivity than HT in improving cognition [24]. The detailed mechanisms underlying HTac benefits remain largely unexplored. We previously observed that HT could protect RPE cells from oxidative stress by activating the Nrf2 signal pathway, thus improving mitochondrial biogenesis and the oxidation status [17,25,26]. Whether HTac can work as an Nrf2 activator in protecting RPE cell functions is still unknown. Despite sharing a similar chemical structure, the similarities and differences of cellular responses to HTac and HT are limited. These are interesting and important aspects of HTac that warrant an extensive investigation.

In this study, we used the human retinal pigment epithelial cell line ARPE-19 to elucidate the potential protective role of HTac. We performed a comparative analysis between HTac and HT on the cellular responses. The results demonstrated that the cells presented different expression profiles under HTac and HT treatments in addition to consistently activating the Nrf2 system. HTac demonstrated a better capacity than HT in activating Nrf2 and protecting ARPE-19 cells against oxidative challenges. This supports its potential use in various disease management approaches, including those for AMD.

2. Materials and Methods

2.1. Chemicals and Reagents

Hydroxytyrosol, hydroxytyrosol acetate, LY294002, PD98059, SP600125, and SB202190 were purchased from TOPSCIENCE (Shanghai, China). The tert-butyl hydroperoxide solution, MTT, and JC-1 were purchased from Sigma (St. Louis, MO, USA). The cell culture medium, H2DCF-DA, and MitoSOX TM Red Mitochondrial superoxide indicator were purchased from Life Technologies (San Diego, CA, USA). The TRIZol reagent, PrimeScript RT-PCR kit, and SYBR PremixExTaq II kit were purchased from Takara (Japan). Antibodies against GAPDH (5174) and histone H1 (41328) were purchased from Cell Signaling

Technology (Danvers, MA, USA). The antibody against Nrf2 (62352) was purchased from Abcam (Cambridge, UK).

2.2. Cell Culture

Human retinal pigment epithelial cell line ARPE-19 was cultured in a DMEM/F12 medium with an HEPES buffer containing 10% fetal bovine serum, 56 mM sodium bicarbonate, 2 mM L-glutamine, 100 U/mL penicillin G sodium, and 100 µg/mL streptomycin sulfate. The cells were maintained at 37 °C in a humidified atmosphere with 5% CO₂. The medium was changed every two days.

2.3. Cell Viability Assay

A cell viability assay was performed using the compound 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT). ARPE-19 cells were seeded in 96-well plates at a density of 2×10^4 cells per well. After the treatment, 200 µL of a serum-free medium containing 5 mg/mL of the MTT solution was added and incubated for 3 h. The medium was then discarded and the cells were washed with PBS. This was followed by the addition of 200 µL DMSO to each well. The absorbance was measured at a wavelength of 490 nm using a microplate fluorometer (Fluoroskan Ascent; Thermo Fisher Scientific, Inc., Vantaa, Finland).

2.4. Mitochondrial Membrane Potential Assay

The mitochondrial membrane potential (MMP) was analyzed using the lipophilic cationic probe 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-imidacarbocyanine iodide (JC-1). ARPE-19 cells were seeded in 96-well plates at a density of 2×10^4 cells per well. After the treatment, the cells were incubated with a serum-free medium containing JC-1 for 1 h. The medium was then discarded and the cells were washed with PBS. The fluorescence was scanned using a microplate fluorometer (FlexStation 3, Molecular Device, San Jose, CA, USA) at a 488 nm excitation wavelength and 538 and 590 nm emission wavelengths, respectively. The red/green fluorescence intensity ratio reflected the MMP.

2.5. Reactive Oxygen Species Analysis

The total cellular reactive oxygen species were analyzed using H2DCF-DA. Mitochondrial superoxides were observed using a MitoSOXTM Red Mitochondrial superoxide indicator. Briefly, the cells were cultured at a density of 1×10^5 cells per well in 6-well plates. After the treatment, the cells were incubated with 10 µM MitoSOXTM Red in a serum-free medium for 10 min or with 20 µM H2DCF-DA in a serum-free medium for 30 min. After washing with PBS, the cells were observed by laser scanning confocal microscopy (Zeiss, Jena, Germany).

2.6. Transcriptomics Analysis

ARPE-19 cells were collected in TRIzol (Invitrogen, 15596018) after the treatments and delivered to Novogene Co., Ltd., (Beijing, China) in dry ice for the RNA-Seq analysis. Briefly, mRNA was purified from the total RNA using poly-T oligo-attached magnetic beads. Reference genome and gene model annotation files were directly downloaded from the genome website. HTSeq v0.9.1 was used to count the numbers of reads mapped to each gene. Genes located by DESeq with an adjusted *p*-value of <0.05 were assigned as differentially expressed. A corrected *p*-value of 0.005 and a log₂ (fold change) of 1 were set as the thresholds for significant differential expressions.

2.7. Real-Time Quantitative PCR

After the treatment, the total RNA of ARPE-19 cells were isolated using the TRIzol reagent, following the manufacturer's protocol. The total RNA pellet was then washed with 75% ethanol and resuspended in DEPC water. The RNA was subjected to reverse transcription using a PrimeScript RT-PCR kit (Takara, Beijing, China). A quantitative real-time PCR analysis was conducted using a SYBR PremixExTaq II kit (Takara, Beijing,

China). The data were normalized to the expression level of β -actin. The detailed primers are presented in Table S1 of the Supplementary Materials.

2.8. Western Blot Analysis

The cells were lysed using a Western blot and an IP lysis buffer (Beyotime, Shanghai, China). The lysates were homogenized on ice and centrifuged at $12,000 \times g$ for 15 min at 4°C . The supernatants were collected and the concentrations were analyzed using a bicinchoninic acid (BCA) protein assay kit. Equal amounts (15 μg) of the protein samples were separated by 10% SDS-PAGE and transferred to pure nitrocellulose membranes blocked with 5% non-fat milk in a TBST buffer. The membranes were incubated with primary antibodies at 4°C overnight, followed by incubation with secondary antibodies at room temperature for 1 h. Chemiluminescent detection was performed using an ECL Western blotting detection kit (Thermo Fisher, Rockford, IL, USA). The images were analyzed using Quantity One software V4.6.7 (Bio-Rad, Shanghai, China) for the density ratio of the target proteins relative to histone H1 or GAPDH.

2.9. Statistical Analysis

All cellular experiments were repeated at least three times. The data were presented as the mean \pm SEM. All statistical analyses were performed using GraphPad software (Prism 9.0, Boston, MA, USA). The significance of the differences between two groups was assessed by an unpaired Student's *t*-test. Multiple groups were analyzed using a one-way ANOVA with Duncan's test. For all comparisons, the level of significance was set at $p < 0.05$.

3. Results

3.1. Effects of HTac and HT on Cell Survival

In our previous study, hydroxytyrosol (HT) was observed to protect ARPE-19 cells against t-BHP-induced mitochondrial dysfunction and cell viability loss at 100 μM [17]. In this study, we confirmed that an HT pretreatment at a dose of 50 μM demonstrated a significant protective effect against a t-BHP challenge. HT at a dose of 10 μM failed (Figure 1A,B). We observed that HTac presented a significant protective effect on the cell viability and mitochondrial membrane potential (MMP) at doses of 10 and 50 μM (Figure 1A,B). The protection was comparable between HTac at 10 μM and HT at 50 μM , which was further supported by cell morphology changes under the t-BHP challenge (Figure 1C). These data suggest that HTac had a larger capacity to protect ARPE-19 cells against oxidative challenges.

3.2. Effects of HTac and HT on Cell Oxidative Stress

It is well-acknowledged that t-BHP can be widely used as an alternative to hydrogen peroxide in oxidative stress studies. In addition to its oxidant properties, t-BHP can also trigger mitochondrial stress and dysfunction to promote cell death [27]. To further characterize the protective effect of HTac and HT against t-BHP-induced oxidative stress, the total cellular reactive oxygen species (ROS) were analyzed using H2DCF-DA and mitochondrial superoxides were observed using MitoSOX staining. As shown in Figure 2, a robust increase in mitochondrial superoxides was observed after the t-BHP treatment, whereas HTac at 10 μM and HT at 50 μM could both efficiently prevent mitochondrial stress (Figure 2A,B). Unlike MitoSOX staining, the DCF staining revealed a certain level of oxidants in the cultured cells under normal conditions, which was elevated after the t-BHP treatment (Figure 2A,B). Consistent with MitoSOX staining, pretreatments of HTac at 10 μM and HT at 50 μM significantly reduced the cellular ROS level (Figure 2A,B). These data indicate that HTac was more efficient than HT at reducing cellular and mitochondrial stress.




Figure 1. The effects of HTac and HT on cell survival. ARPE-19 cells were pretreated with HT at 10 and 50 μM and HTac at 1, 10, and 50 μM for 24 h, followed by 300 μM t-BHP treatment for another 24 h. Cell viability (A) and mitochondrial membrane potential (B) were analyzed. Cell morphology (C) was recorded using a microscope. Scale bar: 10 μm. The values are presented as the mean ± SEM and n = 6. ** $p < 0.01$ between the connected groups.




Figure 2. The effects of HTac and HT on cell oxidative stress. ARPE-19 cells were pretreated with HT at 50 μM and HTac at 10 μM for 24 h, followed by 300 μM t-BHP treatment for another 24 h. Levels of mitochondrial superoxides and cellular reactive oxygen species were analyzed by fluorescent confocal microscopy. (A) Microscopy image; scale bar: 10 μm. (B) Fluorescent intensity analysis of MitoSOX staining. (C) Fluorescent intensity analysis of DCF-DA staining. The values are presented as the mean ± SEM and n = 50. ** $p < 0.01$ between the connected groups.

3.3. HTac Is More Efficient in Activating Phase II Enzymes Than HT

Nrf2 has been well-demonstrated to regulate a series of endogenous antioxidative enzymes, known as phase II enzymes, including HO-1, NQO-1, and GCL [10–12]. The activation of phase II enzymes is suggested to be the major contributor to cellular protection against oxidative damage [28]. Herein, the effects of HTac and HT on the expression of Nrf2-mediated phase II enzymes were further examined. As shown in Figure 3, a short HT pretreatment at 50 μ M had no effect on the total protein level of Nrf2, but could increase the nuclear location of Nrf2. Similar effects were also observed after the HTac treatment at 10 μ M (Figure 3A). HTac at 50 μ M increased both the total and nuclear Nrf2 protein levels (Figure 3A). An analysis of the prolonged treatment for 24 h indicated that only HTac could induce the mRNA expression of Nrf2 (Figure 3B). Consistent with nuclear localization, the target gene expression of Nrf2 (including HO-1, NQO-1, GCLc, and GCLm) was highly induced by HT at 50 μ M and HTac at 10 μ M and 50 μ M (Figure 3C–F). The mRNA expression of these genes induced by HTac at 10 μ M was significantly higher than HT at 50 μ M (Figure 3C–F). These data suggest that HTac was more efficient at activating phase II enzymes than HT.




Figure 3. The effects of HTac and HT on the expression of phase II enzymes. (A) ARPE-19 cells were treated with HT at 10 and 50 μ M and HTac at 1, 10, and 50 μ M for 1 h. The total and nuclear Nrf2 protein levels were analyzed. ARPE-19 cells were treated with HT at 10 and 50 μ M and HTac at 1, 10, and 50 μ M for 24 h. The mRNA levels of Nrf2 (B), HO-1 (C), NQO-1 (D), GCLc (E), and GCLm (F) were analyzed. The values are presented as the mean \pm SEM and n = 3. ** p < 0.01 between the connected groups.

3.4. HTac Protects ARPE-19 Cells via the PI3K/Akt/Erk Pathway

We previously demonstrated that HT could activate c-Jun N-terminal kinase (JNK) to promote the expression of Nrf2-mediated phase II enzymes for the protection of ARPE-19 cells against oxidative challenges [17]. Therefore, we used Akt and MAPK kinase inhibitors

to confirm the major pathway that responded to HTac. Akt inhibitor LY294002, Erk inhibitor PD98059, JNK inhibitor SP600125, and p38 inhibitor SB202190 were incubated with ARPE-19 cells prior to the HTac treatment and following an oxidative challenge. An MMP assay confirmed that HTac could efficiently protect the cell mitochondrial membrane potential, which was significantly inhibited by LY294002 and PD98059 (Figure 4A). A similar effect was also observed for cellular viability (Figure 4B), suggesting that HTac could promote cell survival against oxidative challenges via the PI3K/Akt/Erk pathway. Moreover, short time treatment of HTac could significantly activate PI3K/Akt pathway at dose of 10 μ M, while similar activation was achieved by HT at 50 μ M (Figure 4C,D), further supporting the assumption of HTac having higher capacity than HT in activating phase II enzymes.




Figure 4. HTac protected cells against oxidative damage via the Akt/Erk pathway. ARPE-19 cells were treated with LY294002, PD98059, SP600125, and SB202190 1 h prior to HTac treatment at 10 μ M for 24 h, followed by 300 μ M t-BHP treatment for another 24 h. (A) Mitochondrial membrane potential and (B) cell viability were analyzed. ARPE-19 cells were treated with HT at 10, 50 μ M, and HTac at 10 μ M for 1 h, p-Akt level was analyzed by Western blot ((C) Western blot image; (D) arbitrary unit statistical analysis). The values are presented as the mean \pm SEM and $n = 3$. ** $p < 0.01$, * $p < 0.05$ between the connected groups.

3.5. Cell Transcriptomics Analysis after HTac and HT Treatments

To further investigate the detailed transcriptomics response to HTac and HT treatments, RNA-Seq was employed after HTac and HT treatments for 6 h. The profile of the transcriptome sequence data are shown in Table 1. The four groups presented comparable raw and clean reads; all groups were perfectly mapped to human genomes, with uniquely mapped rates of over 90% (Table 1). The density and distribution of fragments per kilobase per million mapped reads (FPKM) at the transcriptome level among the four groups were detected (Figure 5A,B). The sample correlation tests revealed that there was clear heterogeneity among the four groups of twelve sequencing samples (Figure 5C). Together, the presented data indicated that all the sequencing samples were of a high quality and met the requirement of the subsequent analysis. In the following analysis of differentially expressed genes (DEGs), a fold change of ≥ 1 and $\text{padj} \leq 0.05$ were used as screening thresholds. The

volcano plots of the DEGs demonstrated that the HT treatment at 10 μ M only identified 11 differentially expressed genes, including 4 upregulated genes and 7 downregulated genes (Figure 5D), whereas the HT treatment at 50 μ M identified 67 differentially expressed genes, including 42 upregulated genes and 25 downregulated genes (Figure 5E). The HTac treatment at 10 μ M presented 81 differentially expressed genes, including 29 upregulated genes and 52 downregulated genes (Figure 5F). The detailed gene information is provided in Table S2 of the Supplementary Materials.

Table 1. Statistics for filtering and mapping reads.

Samples	Control-1	Control-2	Control-3	HT 10-1	HT 10-2	HT 10-3	HT 50-1	HT 50-2	HT 50-3	HTac 10-1	HTac 10-2	HTac 10-3
Raw reads	47939032	47880000	45618428	48772208	47614586	46835738	45019930	46509670	49756022	44914942	52660428	47572294
Clean reads	46431720	45692016	44196080	46586116	45334752	45742806	43542056	44870870	48029950	43278854	51208532	46256580
Q20 (%)	97.74	97.97	97.88	97.88	97.93	96.87	97.66	97.86	97.84	97.73	97.87	97.85
Q30 (%)	93.71	94.23	94.08	94.03	94.13	91.5	93.51	94	93.94	93.59	94.04	94
GC content (%)	50.21	50.08	50.29	50.23	50.13	49.6	50.09	50.13	49.96	50.24	50.37	50.35
Total map	44922259	44325313	42804025	45122822	43867105	43618780	42039485	43408363	46436530	41849147	49536077	44737898
Unique map	42413515	45692016	42413515	42524604	41364784	41241266	39632293	40947247	43830529	39526822	46718527	42265694
	(91.35%)	(91.59%)	(91.59%)	(91.28%)	(91.24%)	(90.16%)	(91.02%)	(91.26%)	(91.26%)	(91.33%)	(91.23%)	(91.37%)




Figure 5. Cell transcriptomics response to HTac and HT treatments. ARPE-19 cells were treated with HT at 10 and 50 μ M and HTac at 10 μ M for 6 h. RNA-Seq analysis was performed to reveal cellular transcriptomics response. (A) The density plot of FPKM distribution with $\log_2(\text{FPKM}+1)$ on the horizontal axis and density on the vertical axis. (B) Violin diagram of FPKM distribution with each sample on the horizontal axis and $\log_2(\text{FPKM}+1)$ on the vertical axis. (C) Pearson correlation between samples. (D) Volcano plots of DEGs between HT 10 group and control group. (E) Volcano plots of DEGs between HT 50 group and control group. (F) Volcano plots of DEGs between HTac 10 group and control group. Control group: ARPE-19 cells without treatment; HT 10 group: HT treatment at 10 μ M for 6 h; HT 50 group: HT treatment at 50 μ M for 6 h; HTac 10 group: HTac treatment at 10 μ M for 6 h; n = 3 for each group.

3.6. HTac and HT Present Distinct Cellular Expression Profiles

Both the HTac and HT treatments induced a limited gene expression at the transcriptome level. This could help to better understand the driving mechanisms underlying the various physiological benefits of HTac and HT. Figure 6 presents the heatmaps of the top ten upregulated protein-encoding genes (Figure 6A,B). The HT treatment at 50 μ M significantly increased the expression of genes, including HERPUD1, HMOX1(HO-1), SDF2L1, HSPA5, DNAJB8, MAT2A, MANF, CRELD2, SLC7A11, and TRIM16L (Figure 6A), whereas HTac at 10 μ M induced the expression of HMOX1(HO-1), SLC7A11, CYP1B1, CYP1A1, TRIM16L, SRXN1, PLPP3, TXNDC5, and SLC2A12 (Figure 6B). A further Venn diagram analysis revealed that 5 upregulated and 14 downregulated genes overlapped between the HTac and HT treatment groups (Figure 6C). Among the five upregulated genes, only HO-1 and SLC7A11 have been reported to be target genes of Nrf2 [29]. Whether SLC2A12, RASSF6, and TRIM16L are regulated by Nrf2 requires further investigation. Unlike the upregulated genes, the downregulated genes from the HT treatment all overlapped with the HTac treatment, which also presented another 23 downregulated genes that were not altered in the HT group (Figure 6C; Table S2). All these data indicated that although HTac and HT shared a similar molecular structure, they only presented a small overlapping profile at the transcriptome level. This included the expression of Nrf2-mediated phase II enzymes. The distinct expression profile of HTac compared with HT suggested that HTac may have unique physiological benefits.




Figure 6. Comparison of HTac and HT gene expression profiles. (A) Heatmap of top 10 upregulated genes after HT treatment on ARPE-19 cells. (B) Heatmap of top 10 upregulated genes after HTac treatment on ARPE-19 cells. (C) Venn diagram of the identified DEGs. N = 3 for each group.

4. Discussion

AMD is one of the leading causes of vision loss in the elderly. The dysfunction of RPE cells and the associated damage of retina photoreceptors are the major pathological factors leading to the progression of AMD [30]. Although multiple risk factors have been proposed to promote RPE dysfunction, an excessive production of ROS-associated oxidative stress has been presented as the leading mechanism. ROS-scavenging strategies have demonstrated consistent benefits in maintaining RPE functions [31]. Oxidative-stress-induced RPE cell damage has been well-used as a cellular model for the study of AMD pathology and target therapies.

The Nrf2 pathway is a primary endogenous antioxidative system employed by human cells, including the RPE, to fight against oxidative stress and maintain cellular redox homeostasis. It has been suggested that Nrf2 signaling is impaired in an aging RPE, which increases the risk of developing AMD [32]. The activation of Nrf2 could induce the expression of antioxidative enzymes such as HO-1, NQO-1, GLC, glutathione peroxidase, and glutathione transferase, the activation of which would increase the production of glutathione as well as the total cellular antioxidant capacity [33]. Therefore, Nrf2 has been well-recognized as a therapeutic target for the treatment of AMD. A series of natural compounds, including lipoic acid, lutein/zeaxanthin, and hydroxytyrosol (HT), has been implicated as being beneficial in the treatment of AMD via the targeting of Nrf2 activation [34].

HT is a well-known antioxidant and comprises 40% of the total phenolic compounds in olive oil, which is considered to be the symbol of a Mediterranean diet [35]. No genotoxicity of HT has been reported in humans, and multiple benefits have been revealed in the past decades through extensive studies [36]. We previously reported that HT could prevent diet-induced metabolic syndrome [37] and improve strenuous exercise-associated cardiac pathological changes [38] as well as protecting RPE cells against oxidative stress via activating Nrf2 signaling [17]. Other phenol compounds such as tyrosol and oleuropein have also been reported to activate Nrf2 for the protection of cellular stress and damage [39,40]. Hydroxytyrosol acetate (HTac), as a structural derivative of HT, is a polyphenolic compound present in olive oil. It has received limited attention in the research of Nrf2 signaling. HTac has been suggested to present neuronal and vascular endothelial cell protection as well as antibacterial activity in recent studies [23,24,41], but the effect of HTac on RPE cells remains unknown. Therefore, a comparative study of HTac and HT on RPE cells was performed. Consistent with a previous study [17], we confirmed that HT could protect mitochondrial functions and cell viability against t-BHP at a dose of 50 μ M. HTac demonstrated a similar protection at a dose of 10 μ M. Together with oxidant measurements and an Nrf2 target gene analysis, these data strongly support the notion that HTac is more efficient in activating phase II enzymes and protecting RPE cells than HT.

Nrf2 activity is regulated on multiple levels, including transcriptional, post-transcriptional, and protein-stability regulations. Keap1 is known to be the major binding protein affecting Nrf2 stability, which decreases under normal conditions because Keap1 can bind to Nrf2 for protein degradation. Under oxidative conditions, Keap1 is modified to promote Nrf2 release for the activation of phase II enzymes [9]. Other than Keap1, several kinases (including PI3K/Akt, Erk, p38, and JNK) have been reported to regulate Nrf2 protein stability and activity [42]. We previously demonstrated that HT could promote Nrf2 activity via the activation of the JNK pathway in ARPE-19 cells [17]. HT has also been reported to activate phase II enzymes via the Akt/Erk pathway in vascular endothelial cells [43]. Knowledge of the underlying kinase pathway that contributes to the induction of HTac on Nrf2 is limited. Here, we observed that unlike HT, HTac promoted cell survival against oxidative damage through the Akt/Erk pathway in ARPE-19 cells. The detailed mechanism requires further confirmation.

Although HTac shares the same main chemical structure as HT, they both appear to have distinct cellular transcriptome responses in addition to a small overlapping profile, based on our RNA-Seq analysis. This suggests that HTac has unique biological functions. Among the five upregulated genes that overlapped between the HTac and HT treatment

groups, *HO-1* and *SLC7A11* are known to be regulated by Nrf2 and exert an antioxidative function [44]. Whether *SLC2A12*, *RASSF6*, and *TRIM16L* are the downstream targets of Nrf2 remains unknown. This is the first study to report the induction effect of HTac and HT on these three genes. *SLC2A12* was previously identified as a glucose transporter; its overexpression improved insulin sensitivity in mice [45]. This further supports our previous study that identified the benefits of HT on diabetic mice [37] and suggests that HTac may also have beneficial effects on insulin-sensitivity improvements. *RASSF6* and *TRIM16L* have been identified as tumor-suppressor proteins [46,47]. The increased expression of *RASSF6* by HTac and HT treatments reveals a potential new mechanism of the antitumor effect of HT [48], encouraging the further study of HTac in tumor interventions. Apart from the overlapping upregulated genes, HTac uniquely upregulated the expression of *CYP1B1*, *CYP1A1*, *SRXN1*, *PLPP3*, *TXNDC5*, and *PHRF1*, which suggests the potential effect of HTac in detoxification, stem-cell differentiation, anti-inflammation, and DNA-damage repair [49–51]. The existence of uniquely downregulated genes from the HTac treatment also supports the speculation of distinct activities of HTac that warrant further investigation.

Our study demonstrated that HTac is a nutritional Nrf2 activator, presenting a more effective antioxidative capacity compared with HT in upregulating phase II enzymes and protecting ARPE-19 cells against oxidative challenges. In addition to an overlapping expression profile, HTac could also trigger a unique cellular response despite its similar molecular structure to HT. This suggests a greater number of potential bioactivities of HTac, which should be investigated to support its future employment in various disease management strategies.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/antiox12101834/s1>. Table S1: Detailed primer information; Table S2: Detailed information of DEGs.

Author Contributions: Conceptualization, Z.F., J.L. and J.X.; methodology, X.Z., M.Z., Y.Z., A.Z., L.C., W.C. and X.W.; software, A.Z.; validation, Y.Z., L.C. and W.C.; formal analysis, X.Z., M.Z., Y.Z., A.Z., L.C., W.C. and X.W.; investigation, X.Z., M.Z. and Z.F.; resources, Y.Z., Z.F. and J.L.; data curation, J.X. and Z.F.; writing—original draft preparation, X.Z. and J.X.; writing—review and editing, Z.F. and J.L.; visualization, Z.F.; supervision, J.L.; project administration, L.C. and Z.F.; funding acquisition, X.Z., Z.F. and J.L. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by the National Natural Science Foundation of China Integrated Project of Major Research Plan No. 92249303 and General Projects (Nos. 82100918, 32071154, 32271184, and 82271727), the Taishan Scholars Project of Shandong Province, and the Shandong Provincial Natural Foundation (ZR2023JQ011).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the article.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Mitchell, P.; Liew, G.; Gopinath, B.; Wong, T.Y. Age-related macular degeneration. *Lancet* **2018**, *392*, 1147–1159. [[CrossRef](#)] [[PubMed](#)]
2. Chakravarthy, U.; Peto, T. Current Perspective on Age-Related Macular Degeneration. *JAMA* **2020**, *324*, 794–795. [[CrossRef](#)] [[PubMed](#)]
3. Sharma, R.; Bose, D.; Maminishkis, A.; Bharti, K. Retinal Pigment Epithelium Replacement Therapy for Age-Related Macular Degeneration: Are We There Yet? *Annu. Rev. Pharmacol. Toxicol.* **2020**, *60*, 553–572. [[CrossRef](#)]
4. McBee, J.K.; Van Hooser, J.P.; Jang, G.F.; Palczewski, K. Isomerization of 11-cis-retinoids to all-trans-retinoids in vitro and in vivo. *J. Biol. Chem.* **2001**, *276*, 48483–48493. [[CrossRef](#)] [[PubMed](#)]
5. Guymer, R.H.; Campbell, T.G. Age-related macular degeneration. *Lancet* **2023**, *401*, 1459–1472. [[CrossRef](#)] [[PubMed](#)]

6. Sun, Y.; Zheng, Y.; Wang, C.; Liu, Y. Glutathione depletion induces ferroptosis, autophagy, and premature cell senescence in retinal pigment epithelial cells. *Cell Death Dis.* **2018**, *9*, 753. [[CrossRef](#)]
7. Shu, W.; Baumann, B.H.; Song, Y.; Liu, Y.; Wu, X.; Dunaief, J.L. Ferrous but not ferric iron sulfate kills photoreceptors and induces photoreceptor-dependent RPE autofluorescence. *Redox Biol.* **2020**, *34*, 101469. [[CrossRef](#)]
8. Tang, Z.; Ju, Y.; Dai, X.; Ni, N.; Liu, Y.; Zhang, D.; Gao, H.; Sun, H.; Zhang, J.; Gu, P. HO-1-mediated ferroptosis as a target for protection against retinal pigment epithelium degeneration. *Redox Biol.* **2021**, *43*, 101971. [[CrossRef](#)]
9. Yamamoto, M.; Kensler, T.W.; Motohashi, H. The KEAP1-NRF2 System: A Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. *Physiol. Rev.* **2018**, *98*, 1169–1203. [[CrossRef](#)]
10. Ge, M.; Yao, W.; Yuan, D.; Zhou, S.; Chen, X.; Zhang, Y.; Li, H.; Xia, Z.; Hei, Z. Brg1-mediated Nrf2/HO-1 pathway activation alleviates hepatic ischemia-reperfusion injury. *Cell Death Dis.* **2017**, *8*, e2841. [[CrossRef](#)]
11. El-Shitany, N.A.; Eid, B.G. Icariin modulates carrageenan-induced acute inflammation through HO-1/Nrf2 and NF- κ B signaling pathways. *Biomed. Pharmacother.* **2019**, *120*, 109567. [[CrossRef](#)] [[PubMed](#)]
12. Zhang, Z.; Qu, J.; Zheng, C.; Zhang, P.; Zhou, W.; Cui, W.; Mo, X.; Li, L.; Xu, L.; Gao, J. Nrf2 antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis. *Cell Death Dis.* **2018**, *9*, 83. [[CrossRef](#)] [[PubMed](#)]
13. Ayer, A.; Zarjou, A.; Agarwal, A.; Stocker, R. Heme Oxygenases in Cardiovascular Health and Disease. *Physiol. Rev.* **2016**, *96*, 1449–1508. [[CrossRef](#)] [[PubMed](#)]
14. Ross, D.; Siegel, D. The diverse functionality of NQO1 and its roles in redox control. *Redox Biol.* **2021**, *41*, 101950. [[CrossRef](#)] [[PubMed](#)]
15. Yu, D.; Liu, Y.; Zhou, Y.; Ruiz-Rodado, V.; Larion, M.; Xu, G.; Yang, C. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 9964–9972. [[CrossRef](#)]
16. Xu, X.; Li, M.; Chen, W.; Yu, H.; Yang, Y.; Hang, L. Apigenin Attenuates Oxidative Injury in ARPE-19 Cells thorough Activation of Nrf2 Pathway. *Oxid. Med. Cell. Longev.* **2016**, *2016*, 4378461. [[CrossRef](#)]
17. Zou, X.; Feng, Z.; Li, Y.; Wang, Y.; Wertz, K.; Weber, P.; Fu, Y.; Liu, J. Stimulation of GSH synthesis to prevent oxidative stress-induced apoptosis by hydroxytyrosol in human retinal pigment epithelial cells: Activation of Nrf2 and JNK-p62/SQSTM1 pathways. *J. Nutr. Biochem.* **2012**, *23*, 994–1006. [[CrossRef](#)]
18. You, L.; Peng, H.; Liu, J.; Cai, M.; Wu, H.; Zhang, Z.; Bai, J.; Yao, Y.; Dong, X.; Yin, X.; et al. Catalpol Protects ARPE-19 Cells against Oxidative Stress via Activation of the Keap1/Nrf2/ARE Pathway. *Cells* **2021**, *10*, 2635. [[CrossRef](#)]
19. Liu, B.; Wang, W.; Shah, A.; Yu, M.; Liu, Y.; He, L.; Dang, J.; Yang, L.; Yan, M.; Ying, Y.; et al. Sodium iodate induces ferroptosis in human retinal pigment epithelium ARPE-19 cells. *Cell Death Dis.* **2021**, *12*, 230. [[CrossRef](#)]
20. Lisete-Torres, P.; Losada-Barreiro, S.; Albuquerque, H.; Sánchez-Paz, V.; Paiva-Martins, F.; Bravo-Díaz, C. Distribution of hydroxytyrosol and hydroxytyrosol acetate in olive oil emulsions and their antioxidant efficiency. *J. Agric. Food Chem.* **2012**, *60*, 7318–7325. [[CrossRef](#)]
21. de Pablos, R.M.; Espinosa-Oliva, A.M.; Hornedo-Ortega, R.; Cano, M.; Arguelles, S. Hydroxytyrosol protects from aging process via AMPK and autophagy; a review of its effects on cancer, metabolic syndrome, osteoporosis, immune-mediated and neurodegenerative diseases. *Pharmacol. Res.* **2019**, *143*, 58–72. [[CrossRef](#)] [[PubMed](#)]
22. Romero, C.; Brenes, M.; Yousfi, K.; Garcia, P.; Garcia, A.; Garrido, A. Effect of cultivar and processing method on the contents of polyphenols in table olives. *J. Agric. Food Chem.* **2004**, *52*, 479–484. [[CrossRef](#)] [[PubMed](#)]
23. Yao, F.; Jin, Z.; Lv, X.; Zheng, Z.; Gao, H.; Deng, Y.; Liu, Y.; Chen, L.; Wang, W.; He, J.; et al. Hydroxytyrosol Acetate Inhibits Vascular Endothelial Cell Pyroptosis via the HDAC11 Signaling Pathway in Atherosclerosis. *Front. Pharmacol.* **2021**, *12*, 656272. [[CrossRef](#)] [[PubMed](#)]
24. Qin, C.; Hu, S.; Zhang, S.; Zhao, D.; Wang, Y.; Li, H.; Peng, Y.; Shi, L.; Xu, X.; Wang, C.; et al. Hydroxytyrosol Acetate Improves the Cognitive Function of APP/PS1 Transgenic Mice in ER β -dependent Manner. *Mol. Nutr. Food Res.* **2021**, *65*, e2000797. [[CrossRef](#)] [[PubMed](#)]
25. Zhu, L.; Liu, Z.; Feng, Z.; Hao, J.; Shen, W.; Li, X.; Sun, L.; Sharman, E.; Wang, Y.; Wertz, K.; et al. Hydroxytyrosol protects against oxidative damage by simultaneous activation of mitochondrial biogenesis and phase II detoxifying enzyme systems in retinal pigment epithelial cells. *J. Nutr. Biochem.* **2010**, *21*, 1089–1098. [[CrossRef](#)]
26. Liu, Z.; Sun, L.; Zhu, L.; Jia, X.; Li, X.; Jia, H.; Wang, Y.; Weber, P.; Long, J.; Liu, J. Hydroxytyrosol protects retinal pigment epithelial cells from acrolein-induced oxidative stress and mitochondrial dysfunction. *J. Neurochem.* **2007**, *103*, 2690–2700. [[CrossRef](#)]
27. Zhao, W.; Feng, H.; Sun, W.; Liu, K.; Lu, J.J.; Chen, X. Tert-butyl hydroperoxide (t-BHP) induced apoptosis and necroptosis in endothelial cells: Roles of NOX4 and mitochondrion. *Redox Biol.* **2017**, *11*, 524–534. [[CrossRef](#)]
28. Zou, X.; Gao, J.; Zheng, Y.; Wang, X.; Chen, C.; Cao, K.; Xu, J.; Li, Y.; Lu, W.; Liu, J.; et al. Zeaxanthin induces Nrf2-mediated phase II enzymes in protection of cell death. *Cell Death Dis.* **2014**, *5*, e1218. [[CrossRef](#)]
29. Qi, D.; Chen, P.; Bao, H.; Zhang, L.; Sun, K.; Song, S.; Li, T. Dimethyl fumarate protects against hepatic ischemia-reperfusion injury by alleviating ferroptosis via the NRF2/SLC7A11/HO-1 axis. *Cell Cycle* **2023**, *22*, 818–828. [[CrossRef](#)]
30. Bellezza, I. Oxidative Stress in Age-Related Macular Degeneration: Nrf2 as Therapeutic Target. *Front. Pharmacol.* **2018**, *9*, 1280. [[CrossRef](#)]
31. Tisi, A.; Pulcini, F.; Carozza, G.; Mattei, V.; Flati, V.; Passacantando, M.; Antognelli, C.; Maccarone, R.; Delle Monache, S. Antioxidant Properties of Cerium Oxide Nanoparticles Prevent Retinal Neovascular Alterations In Vitro and In Vivo. *Antioxidants* **2022**, *11*, 1133. [[CrossRef](#)] [[PubMed](#)]

32. Sachdeva, M.M.; Cano, M.; Handa, J.T. Nrf2 signaling is impaired in the aging RPE given an oxidative insult. *Exp. Eye Res.* **2014**, *119*, 111–114. [[CrossRef](#)] [[PubMed](#)]
33. Kobayashi, M.; Yamamoto, M. Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation. *Antioxid. Redox Signal.* **2005**, *7*, 385–394. [[CrossRef](#)] [[PubMed](#)]
34. Cai, Z.Y.; Fu, M.D.; Liu, K.; Duan, X.C. Therapeutic effect of Keap1-Nrf2-ARE pathway-related drugs on age-related eye diseases through anti-oxidative stress. *Int. J. Ophthalmol.* **2021**, *14*, 1260–1273. [[CrossRef](#)]
35. Bayram, B.; Esatbeyoglu, T.; Schulze, N.; Ozcelik, B.; Frank, J.; Rimbach, G. Comprehensive analysis of polyphenols in 55 extra virgin olive oils by HPLC-ECD and their correlation with antioxidant activities. *Plant Foods Hum. Nutr.* **2012**, *67*, 326–336. [[CrossRef](#)] [[PubMed](#)]
36. Vijakumar, U.; Shanmugam, J.; Heng, J.W.; Azman, S.S.; Yazid, M.D.; Haizum Abdullah, N.A.; Sulaiman, N. Effects of Hydroxytyrosol in Endothelial Functioning: A Comprehensive Review. *Molecules* **2023**, *28*, 1861. [[CrossRef](#)]
37. Cao, K.; Xu, J.; Zou, X.; Li, Y.; Chen, C.; Zheng, A.; Li, H.; Li, H.; Szeto, I.M.; Shi, Y.; et al. Hydroxytyrosol prevents diet-induced metabolic syndrome and attenuates mitochondrial abnormalities in obese mice. *Free Radic. Biol. Med.* **2014**, *67*, 396–407. [[CrossRef](#)]
38. Xiong, Y.; Xu, J.; Cao, W.; Zhang, J.; Feng, Z.; Cao, K.; Liu, J. Hydroxytyrosol improves strenuous exercise-associated cardiac pathological changes via modulation of mitochondrial homeostasis. *Food Funct.* **2022**, *13*, 8676–8684. [[CrossRef](#)]
39. Delle Monache, S.; Pulcini, F.; Frosini, R.; Mattei, V.; Talesa, V.N.; Antognelli, C. Methylglyoxal-Dependent Glycative Stress Is Prevented by the Natural Antioxidant Oleuropein in Human Dental Pulp Stem Cells through Nrf2/Glo1 Pathway. *Antioxidants* **2021**, *10*, 716. [[CrossRef](#)]
40. Guvenc, M.; Cellat, M.; Gokcek, I.; Arkali, G.; Uyar, A.; Tekeli, I.O.; Yavas, I. Tyrosol prevents AlCl₃ induced male reproductive damage by suppressing apoptosis and activating the Nrf-2/HO-1 pathway. *Andrologia* **2020**, *52*, e13499. [[CrossRef](#)]
41. Wei, J.; Wang, S.; Pei, D.; Qu, L.; Li, Y.; Chen, J.; Di, D.; Gao, K. Antibacterial Activity of Hydroxytyrosol Acetate from Olive Leaves (*Olea europaea* L.). *Nat. Prod. Res.* **2018**, *32*, 1967–1970. [[CrossRef](#)] [[PubMed](#)]
42. Tonelli, C.; Chio, I.I.C.; Tuveson, D.A. Transcriptional Regulation by Nrf2. *Antioxid. Redox Signal.* **2018**, *29*, 1727–1745. [[CrossRef](#)]
43. Zrelli, H.; Matsuoka, M.; Kitazaki, S.; Araki, M.; Kusunoki, M.; Zarrouk, M.; Miyazaki, H. Hydroxytyrosol induces proliferation and cytoprotection against oxidative injury in vascular endothelial cells: Role of Nrf2 activation and HO-1 induction. *J. Agric. Food Chem.* **2011**, *59*, 4473–4482. [[CrossRef](#)] [[PubMed](#)]
44. Dong, H.; Qiang, Z.; Chai, D.; Peng, J.; Xia, Y.; Hu, R.; Jiang, H. Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. *Aging* **2020**, *12*, 12943–12959. [[CrossRef](#)] [[PubMed](#)]
45. Purcell, S.H.; Aerni-Flessner, L.B.; Willcockson, A.R.; Diggs-Andrews, K.A.; Fisher, S.J.; Moley, K.H. Improved insulin sensitivity by GLUT12 overexpression in mice. *Diabetes* **2011**, *60*, 1478–1482. [[CrossRef](#)]
46. Hossain, S.; Iwasa, H.; Sarkar, A.; Maruyama, J.; Arimoto-Matsuzaki, K.; Hata, Y. The RASSF6 Tumor Suppressor Protein Regulates Apoptosis and Cell Cycle Progression via Retinoblastoma Protein. *Mol. Cell. Biol.* **2018**, *38*, e00046-18. [[CrossRef](#)]
47. Yin, L.; Zhou, L.; Xu, R. Identification of Tumor Mutation Burden and Immune Infiltrates in Hepatocellular Carcinoma Based on Multi-Omics Analysis. *Front. Mol. Biosci.* **2020**, *7*, 599142. [[CrossRef](#)]
48. Imran, M.; Nadeem, M.; Gilani, S.A.; Khan, S.; Sajid, M.W.; Amir, R.M. Antitumor Perspectives of Oleuropein and Its Metabolite Hydroxytyrosol: Recent Updates. *J. Food Sci.* **2018**, *83*, 1781–1791. [[CrossRef](#)]
49. Montane-Romero, M.E.; Martinez-Silva, A.V.; Poot-Hernandez, A.C.; Escalante-Alcalde, D. Plpp3, a novel regulator of pluripotency exit and endodermal differentiation of mouse embryonic stem cells. *Biol. Open* **2023**, *12*, bio059665. [[CrossRef](#)]
50. Chang, C.F.; Chu, P.C.; Wu, P.Y.; Yu, M.Y.; Lee, J.Y.; Tsai, M.D.; Chang, M.S. PHRF1 promotes genome integrity by modulating non-homologous end-joining. *Cell Death Dis.* **2015**, *6*, e1716. [[CrossRef](#)]
51. Zhou, Y.; Duan, S.; Zhou, Y.; Yu, S.; Wu, J.; Wu, X.; Zhao, J.; Zhao, Y. Sulfiredoxin-1 attenuates oxidative stress via Nrf2/ARE pathway and 2-Cys Prdxs after oxygen-glucose deprivation in astrocytes. *J. Mol. Neurosci.* **2015**, *55*, 941–950. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.